Table 3 Clinicopathologic comparisons between EML4–ALK fusion-positive and fusion-negative lung adenocarcinomas
From: Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement
Overall | EML4–ALK(+) | EML4–ALK(−) | ||
|---|---|---|---|---|
n = 287 | n = 37 (%) | n = 250 (%) | P value | |
Age | Mean ± SD | 48.16 ± 11.529 | 58.17 ± 10.03 | <0.001 |
Median | 48 | 58 | ||
Range | 24-70 | 25-81 | ||
Sex | Male | 20(13.1) | 133(86.9) | 0.999 |
Female | 17(13.1) | 113(86.9) | ||
Nonavailable | 0 | 4 | ||
Smoking | Never smoker | 22(13.8) | 138(86.2) | 0.239 |
Ever smoker | 9(8.9) | 92(91.1) | ||
Nonavailable | 6 | 20 | ||
Tumor size(mm) | Mean ± SD | 38.42 ± 24.263 | 37.59 ± 16.837 | 0.872 |
Median | 32.50 | 35.00 | ||
Range | 7-100 | 10-90 | ||
pT status | pT1 | 4(13.8) | 25(86.2) | 0.350 |
pT2 | 14(8.3) | 154(91.7) | ||
pT3-T4 | 5(15.6) | 27(84.4) | ||
Nonavailable | 14 | 44 | ||
pN status | pN0 | 2(2.0) | 100(98.0) | 0.002 |
pN1 | 11(16.7) | 55(83.3) | ||
pN2-3 | 7(13.5) | 45(86.5) | ||
Nonavailable | 17 | 50 | ||
pTNM stages | pStage I | 2(2.5) | 79(97.5) | 0.028 |
pStage II | 9(12.2) | 65(87.8) | ||
pStage III | 9(14.3) | 54(85.7) | ||
Nonavailable | 17 | 52 |